ArticleClinical rheumatology2025
Investigation of hub-shared genes and regulatory mechanisms of rheumatoid arthritis and atherosclerosis.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- γδ T Cells in Autoinflammatory Diseases.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveStudy found that patients with rheumatoid arthritis (RA) are more likely to develop atherosclerosis than normal adults. However, their shared mechanisms of action still remain unclear. This study aimed to identify the shared genes between the two diseases and uncover their regulatory mechanisms.
methodThe RA- and atherosclerosis-related microarray datasets were downloaded from public databases. Gene set enrichment, differential expression, and weighted gene co-expression network analyses were performed to identify the shared genes between the two diseases. Functional enrichment analysis and protein-protein interaction networks for shared genes were performed. Through further expression validation using validation datasets, hub-shared genes were identified. The diagnostic values of hub-shared genes and their related transcription factors (TFs), small-molecule drugs, and immune cells were analyzed.
resultsA total of 82 shared genes, which were significantly involved in nine pathways, including the peroxisome proliferator-activated receptor signaling pathway and Th1 and Th2 cell differentiation, were identified. Two hub-shared genes, CD52 and TNFRSF17, were screened out using validation. CD52 and TNFRSF17 showed high diagnostic performance for both diseases. CD52 and TNFRSF17 could interact with multiple proteins, including TNFSF13, and are regulated by several TFs, including NFKB1 and MEF2A. Moreover, significant correlations were observed between hub-shared genes and the infiltration of several immune cells in the two diseases, such as between gamma delta T cells and TNFRSF17, as well as between neutrophils and CD52.
conclusionTwo hub-shared genes, CD52 and TNFRSF17, may be key regulators in the development of RA and atherosclerosis. Key Points • Study found that patients with RA are more likely to develop atherosclerosis. The shared mechanisms of action between the two diseases are unclear. We used bioinformatics methods to investigate shared genes and explore the mechanisms. • Our results indicated that the two hub genes, CD52 and TNFRSF17, may be key regulators in the development of atherosclerosis in RA. Further research of these two genes may reveal the mechanism that RA patients are more likely to suffer from atherosclerosis.
Indexed as
Identifiers
40289029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.